California Debates Whether to Become Stem Cell Heavyweight
By Gretchen Vogel,
Science
| 09. 10. 2004
[Quotes CGS's Richard Hayes]
California Debates Whether to Become Stem Cell Heavyweight
Gretchen Vogel
Science
September 10, 2004
President George W. Bush may end up doing California stem cell researchers a huge favor. Spurred by the Bush Administration's restrictions on funding for human embryonic stem (ES) cells, patient advocates, venture capitalists, and research leaders have launched a campaign to persuade California voters to pass an unprecedented ballot proposal, called Proposition 71, that would allocate $3 billion for the field over the next 10 years.
If the measure passes in November--and early polls say it's still too close to call (Science, 27 August, p. 1225)--California would spend nearly $300 million a year on human ES cell research, almost 50% more than the $214 million the National Institutes of Health (NIH) spent on all human stem cell research--both embryonic and nonembryonic--in 2003. "It will change the landscape of where this work is done," says Douglas Melton of Harvard University, who because of the White House's restrictions has had to set up a privately funded lab to derive new human ES cell lines. "California will become a...
Related Articles
By Tomoko Otake, The Japan Times | 04.09.2024
A decade ago, researcher Haruko Obokata caused a sensation when she published two papers in the journal Nature, in which she claimed that she had discovered a way to create stem cells easily using the so-called STAP method.
With STAP...
By Ian Sample, The Guardian | 03.08.2024
Scientists are a step closer to making IVF eggs from patients’ skin cells after adapting the procedure that created Dolly the sheep, the first cloned mammal, more than two decades ago.
The work raises the prospect of older women being...
By Ramon Antonio Vargas, The Guardian | 02.28.2024
Doctors say a man in California who contracted blood cancer while living with HIV is in remission from both potentially fatal illnesses thanks to a treatment they are hailing as remarkable and encouraging.
Paul Edmonds is only the fifth-known person...
By Victoria Gray, Uduak Thomas, and Kevin Davies, The CRISPR Journal | 02.14.2024
In July 2019, medical staff in Nashville dosed the first U.S. patient in the exa-cel therapy trial, sponsored by Vertex Pharmaceuticals and CRISPR Therapeutics. That first patient was Victoria Gray, a mother of four from Forest, Mississippi, a sickle cell...